Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tepnel, SoftGenetics team up for congenital disorder tests

This article was originally published in Clinica

Executive Summary

Manchester, UK-based IVD company Tepnel Life Sciences and US developer of genetic diagnostics software SoftGenetics have brought together their respective know-how in gene testing to offer rapid tests for congenital disorders in foetuses. Tepnel is now offering its Elucigene QST*R tests for the prenatal detection of common chromosome abnormalities together with SoftGenetics GeneMarker genotyping software. The range of disorders that the QST*R tests for include Down syndrome, Edwards syndrome and Patau syndrome. Tepnel said that the combination of the two products helps to streamline the data analysis process and shorten the results reporting time for users of the QST*R tests. Results can be obtained within four hours. A spokesperson for Tepnel told Clinica that the company will in the future be rolling out the GeneMarker in combination with other tests from its Elucigene range.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041753

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel